Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL458175 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL4067496 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL8850904 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL1594598 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL3298712 | 1.00 | — | — | |
| Methylene Chloride SCHEMBL9277901 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL6391133 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL9835580 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL17451199 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 | |
| Methylene Chloride SCHEMBL9275227 | 1.00 | THRB (0.35) | THRBTP53TSHRTDP1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800976-A | Nitrogen-containing heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3059238-B1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-05-27 | — | — | EP | disclosed |
| US-10174021-B2 | Substituted pyrazolo[1,5-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-20170313700-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9656996-B2 | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-23 | — | — | US | disclosed |
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| EP-3059238-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2016-08-24 | — | — | EP | disclosed |
| EP-0894787-B1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXYLATE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-6136852-A | 3,4-disubstituted phenylethanolaminotetralincarboxylic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| EP-0894787-A1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXYLATE DERIVATIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244432-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3R5 | THRB 2954/4885TP53 343/4885TSHR 3696/4885 |
| US-10174021-B2 | Substituted pyrazolo[1,5-A]pyridines and their use | PNPO, PDXK, XDH | THRB 1732/4885TP53 2505/4885TSHR 2635/4885 |
| US-20170313700-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE | PNPO, TPMT, PDXK | THRB 2122/4885TP53 1442/4885TSHR 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.